Ronald E. DeGryse

3.7k total citations · 1 hit paper
46 papers, 2.7k citations indexed

About

Ronald E. DeGryse is a scholar working on Psychiatry and Mental health, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, Ronald E. DeGryse has authored 46 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Psychiatry and Mental health, 20 papers in Physiology and 19 papers in Pathology and Forensic Medicine. Recurrent topics in Ronald E. DeGryse's work include Migraine and Headache Studies (28 papers), Botulinum Toxin and Related Neurological Disorders (17 papers) and Sympathectomy and Hyperhidrosis Treatments (17 papers). Ronald E. DeGryse is often cited by papers focused on Migraine and Headache Studies (28 papers), Botulinum Toxin and Related Neurological Disorders (17 papers) and Sympathectomy and Hyperhidrosis Treatments (17 papers). Ronald E. DeGryse collaborates with scholars based in United States, Ireland and Germany. Ronald E. DeGryse's co-authors include Catherine C. Turkel, Stephen D. Silberstein, David W. Dodick, Richard B. Lipton, Mitchell F. Brin, Sheena K. Aurora, Hans‐Christoph Diener, Hans‐Christoph Diener, Sheena K. Aurora and Marissa E. Nolan and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Annals of the New York Academy of Sciences.

In The Last Decade

Ronald E. DeGryse

44 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program

2010 665 citations David W. Dodick, Catherine C. Turkel et al. Headache The Journal of Head and Face Pain profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ronald E. DeGryse United States	24	2.0k	1.4k	1.2k	943	286	46	2.7k
Rigmor Jensen Denmark	10	1.7k 0.8×	851 0.6×	748 0.6×	212 0.2×	171 0.6×	13	2.0k
Thien Phu Denmark	18	1.6k 0.8×	705 0.5×	462 0.4×	280 0.3×	136 0.5×	43	1.9k
Gennaro Bussone Italy	23	1.3k 0.7×	887 0.6×	541 0.4×	297 0.3×	188 0.7×	113	1.8k
Todd D. Rozen United States	26	1.9k 0.9×	1.3k 0.9×	913 0.7×	547 0.6×	263 0.9×	124	2.4k
Maurice Vincent Brazil	22	1.1k 0.5×	782 0.6×	408 0.3×	255 0.3×	116 0.4×	110	1.6k
Derya Uludüz Türkiye	22	1.6k 0.8×	792 0.6×	434 0.3×	275 0.3×	244 0.9×	83	2.0k
T. A. Fredriksen Norway	22	1.3k 0.6×	1.2k 0.9×	524 0.4×	344 0.4×	390 1.4×	46	2.1k
Susanna Usai Italy	28	1.8k 0.9×	1.1k 0.8×	582 0.5×	318 0.3×	232 0.8×	95	2.2k
J.N. Blau United Kingdom	24	1.3k 0.6×	690 0.5×	442 0.4×	205 0.2×	186 0.7×	69	1.8k
Christian Lampl Austria	20	1.3k 0.7×	743 0.5×	424 0.3×	162 0.2×	144 0.5×	42	1.5k

Countries citing papers authored by Ronald E. DeGryse

Since Specialization

Citations

This map shows the geographic impact of Ronald E. DeGryse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald E. DeGryse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald E. DeGryse more than expected).

Fields of papers citing papers by Ronald E. DeGryse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald E. DeGryse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald E. DeGryse. The network helps show where Ronald E. DeGryse may publish in the future.

Co-authorship network of co-authors of Ronald E. DeGryse

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald E. DeGryse. A scholar is included among the top collaborators of Ronald E. DeGryse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald E. DeGryse. Ronald E. DeGryse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Diener, Hans‐Christoph, David W. Dodick, Richard B. Lipton, et al.. (2020). Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis. SHILAP Revista de lepidopterología. 9(2). 683–694. 8 indexed citations

McAlindon, Timothy E., et al.. (2018). Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study. Osteoarthritis and Cartilage. 26(10). 1291–1299. 17 indexed citations

Kalunian, Kenneth, Lars Arendt‐Nielsen, Catherine C. Turkel, et al.. (2014). Results from a single center, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy and safety of intra-articular onabotulinumtoxina for osteoarthritis knee pain. Osteoarthritis and Cartilage. 22. S192–S192. 6 indexed citations

Silberstein, Stephen D., David W. Dodick, Sheena K. Aurora, et al.. (2014). Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. Journal of Neurology Neurosurgery & Psychiatry. 86(9). 996–1001. 110 indexed citations

Dodick, David W., Catherine C. Turkel, Ronald E. DeGryse, et al.. (2014). Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example. Journal of Pain. 16(2). 164–175. 53 indexed citations

Arendt‐Nielsen, Lars, Guangliang Jiang, Ronald E. DeGryse, & Catherine C. Turkel. (2014). A single center, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy and safety of intra-articular onabotulinumtoxina as treatment for osteoarthritis knee pain: results from the experimental pain models. Osteoarthritis and Cartilage. 22. S26–S26. 2 indexed citations

Silberstein, Stephen D., Andrew Blumenfeld, Roger Cady, et al.. (2013). OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. Journal of the Neurological Sciences. 331(1-2). 48–56. 149 indexed citations

Saper, Joel R., et al.. (2007). A Double-Blind, Randomized, Placebo-Controlled Comparison of Botulinum Toxin Type A Injection Sites and Doses in the Prevention of Episodic Migraine. Pain Medicine. 8(6). 478–485. 48 indexed citations

Elkind, Arthur H., et al.. (2006). A Series of Three Sequential, Randomized, Controlled Studies of Repeated Treatments With Botulinum Toxin Type A for Migraine Prophylaxis. Journal of Pain. 7(10). 688–696. 63 indexed citations

10.

Dodick, David W., Alexander Mauskop, Arthur H. Elkind, et al.. (2005). Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled Study. Headache The Journal of Head and Face Pain. 45(4). 315–324. 154 indexed citations

11.

Brint, Stephen F., et al.. (1999). Efficacy and safety of nonpreservedketorolac ophthalmic solution in postoperative ocular pain following radial keratotomy. Journal of Cataract & Refractive Surgery. 25(1). 41–49. 9 indexed citations

12.

Cheetham, Janet K., Ronald E. DeGryse, Monte S. Dirks, et al.. (1999). Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery:. American Journal of Ophthalmology. 127(3). 253–259. 58 indexed citations

13.

Gimbel, Howard V., et al.. (1996). Intraocular availability and pupillary effect of flurbiprofen and indomethacin during cataract surgery. Journal of Cataract & Refractive Surgery. 22(4). 474–479. 9 indexed citations

14.

Ginsburg, Arthur P., et al.. (1995). Effects of flurbiprofen and indomethacin on acute cystoid macular edema after cataract surgery: Functional vision and contrast sensitivity. Journal of Cataract & Refractive Surgery. 21(1). 82–92. 31 indexed citations

15.

Gwon, Arlene, et al.. (1994). Ocufen (flurbiprofen) in the treatment of ocular pain after radial keratotomy.. PubMed. 20(2). 131–8. 17 indexed citations

16.

Walt, John G., et al.. (1993). Flurbiprofen 0.03% for the control of inflammation following cataract extraction by phacoemulsification. Journal of Cataract & Refractive Surgery. 19(4). 481–487. 18 indexed citations

17.

Smith, Edgar B., Debra Breneman, Adelaide A. Hebert, et al.. (1992). Double-blind comparison of naftifine cream and clotrimazole/betamethasone dipropionate cream in the treatment of tinea pedis. Journal of the American Academy of Dermatology. 26(1). 125–127. 33 indexed citations

18.

Smith, Edgar B., Karen Wiss, Jon M. Hanifin, et al.. (1990). Comparison of once- and twice-daily naftifine cream regimens with twice-daily clotrimazole in the treatment of tinea pedis. Journal of the American Academy of Dermatology. 22(6). 1116–1117. 19 indexed citations

19.

Jordon, Robert E., Ronald P. Rapini, H. Irving Katz, et al.. (1990). Once‐Daily Naftifine Cream 1% in the Treatment of Tinea Cruris and Tinea Corporis. International Journal of Dermatology. 29(6). 441–442. 9 indexed citations

20.

Schachner, Lawrence A., et al.. (1990). The safety and efficacy of naftifine cream 1% in the treatment of tinea pedis. 7(3). 148–152. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact